Marico Q1 FY26 revenue rose 23%; resurfacing August move to raise Plix maker stake to 60%

Resurfacing an August 2025 update, Marico reported Q1 FY26 net profit of Rs 513 crore, up 8.2% year on year, as revenue from operations rose 23.3% to Rs 3,259 crore. India revenue grew 27.2% to Rs 2,495 crore, while international revenue increased 12.9%. The company also increased its fully diluted stake in Satiya Nutraceuticals, which owns Plix, to 60%.

— FiledFri, 11 Sept, 2026, 05:34 IST·First seen Fri, 11 Sept, 2026, 05:34 IST·Source Financial Express · BrandWagon

What happened

Marico posted Q1 FY26 profit growth of 8.2% and revenue growth of 23.3%, led by a 27.2% rise in India sales. It increased its stake in Plix maker Satiya

Key facts

  • Q1 FY26 consolidated net profit: Rs 513 crore, up 8.2% YoY from Rs 474 crore
  • Revenue from operations: Rs 3,259 crore, up 23.31% YoY from Rs 2,643 crore
  • Total income: Rs 3,315 crore, including Rs 56 crore other income
  • India revenue: Rs 2,495 crore, up 27.17% YoY from Rs 1,962 crore
  • International revenue: Rs 764 crore, up 12.91% YoY from Rs 681 crore
  • India segment PBT: Rs 469 crore
  • International segment profit: Rs 213 crore
  • Total expenses: Rs 2,659 crore, versus Rs 2,075 crore
  • Marico increased Satiya Nutraceuticals stake to 60% on a fully diluted basis

Why this matters

Raising its Plix-maker stake to 60% gives Marico control over a scaled wellness platform and strengthens its ability to capture premium, digital-first consumer trends.

What to watch

  • India volume growth versus price/mix contribution in subsequent quarters.
  • Plix revenue growth, EBITDA trajectory, channel expansion and any further stake-acquisition terms.
  • Gross-margin movement amid copra, edible-oil, crude-linked packaging and currency changes.
  • Whether international growth re-accelerates or remains below India growth.
  • Competitive activity in protein, supplements and digital-first wellness brands.
  • Scale Plix distribution into modern trade, pharmacies and selected general-trade outlets while preserving D2C positioning.
  • Increase cross-category marketing around nutrition, personal care and wellness to lift premium product penetration.
  • Use majority control to integrate procurement, supply chain and back-end operations at Satiya Nutraceuticals.
  • Prioritise margin protection through calibrated pricing, pack-size actions and commodity hedging.